The marketing authorisation for Pulsaflox has been withdrawn at the request of the marketing authorisation holder.
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
|Date of issue of marketing authorisation valid throughout the European Union||
1ère Avenue 2065 M - L.I.D.
25/03/2010 Pulsaflox - EMEA/V/C/000060 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Antibacterials for systemic use
In chickens and turkeys Pulsaflox oral solution is indicated for treatment of chronic respiratory infections caused by sensitive strains of Escherichia coli and Mycoplasma gallisepticum.
In turkeys Pulsaflox oral solution is also indicated for the treatment of infections caused by Pasteurella multocida.
Pulsaflox oral solution should only be used based on susceptibility testing.